直擊特斯拉AI日:人形機器人擎天柱Optimus原型機正式亮相
北京時間10月1日上午消息,特斯拉史上的第二個AI日活動在美國加州帕洛阿託舉辦。

此次AI日最大的看點自然首次亮相的特斯拉機器人“擎天柱”(Optimus)原型機。除此之外,特斯拉還預吿了“老本行”自動駕駛(FSD)領域的新進展,包括最受關注的Dojo超級計算機。

馬斯克首先帶來了特斯拉人形機器人Optimus原型機,並通過一段視頻展示了該機器人能做的搬運、澆水等操作。接着,馬斯克展示了“擎天柱”機器人準備投產的版本。


馬斯克表示,目標是儘快製造出有用的人形機器人。馬斯克預計“擎天柱”人形機器人產量將達數百萬台,且價格比汽車便宜的多,預計每台2萬美元。
持續更新中......
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.